Hepatitis C New Drug Research And Liver Health
  • HCV News Of The Day
    • 2013/HCV Drugs News Digest
    • HCV Drugs: News Digest>
      • News Archive
      • Liver HCV : Specialty news digest
  • 2013 - Breaking Conference Reports/Hepatitis C
    • Breaking Conference Reports >
      • EASL 2012 Meeting Summary>
        • EASL Summary Of The 2011 March Meeting
      • AASLD- Nov 2011 Annual Meeting>
        • Conference Archive
  • Blog: New HCV Drug Updates
  • HCV FAQ
  • HCV: Newly Diagnosed?
    • Challenges-issues in managing hepatitis C
    • Ask Me A Question About Hepatitis C
  • What to do with a positive hepatitis C test
  • 2013-HCV Abstract Corner
    • HCV Abstract Corner>
      • Archive; Abstract Corner
  • 2013-Hepatitis C Full Text Articles
    • Hepatitis C Treatment Complete Studies 2012>
      • Potential new method to block the lifecycle of the Hepatitis C virus
      • Hepatitis C Treatment Complete Studies 2011
  • 2013/HCV Multimedia Videos Podcasts
    • Multimedia/Videos-Podcasts>
      • Watch How Hepatitis C Protease Inhibitors Work>
        • Multimedia; Archives Videos and Podcasts
  • 2013 Stem Cell News and Research
    • Liver-2012 Stem Cell Updates
    • Liver: 2011 Stem Cell Updates
    • What Are Stem Cells?>
      • Future applications of human stem cells
  • Recommended; Stem Cell Blogs
  • Understanding Hepatitis C
  • Natural History Of HCV
    • A 20-year cohort study on the natural history of untreated HCV infection
  • Hepatitis C Disease Progression
    • NIH scientists identify likely predictors of hepatitis C severity
    • HCV Epidemiology, Diagnosis and Disease Progression
    • Hepatitis C may increase deaths from both liver-related and other diseases>
      • Mortality in advanced HCV /long-term peginterferon
    • Host Factors on Management of HCV
  • Transmission
    • How Soon To Initiate HCV Therapy After Transmission
    • Does the Hepatitis C virus survive in dried blood ?
    • Viral Load Tied to Vertical Transmission of Hepatitis C
    • Hey Can I Get Hep C From......
    • HCV infections transmitted via a clinical setting
    • What Should I Do If I Get A Needlestick
  • How are the different types of hepatitis transmitted
    • New challenges in viral hepatitis
    • Hepatitis A virus infection in high-risk subjects
  • Your Liver Functions
  • Liver Function Tests
    • HCV-Persistently Normal (ALT) Alanine Aminotransferase Levels
    • Hey, I have a question about hcv tests and my liver
    • ALT used to separate those infected with HCV from those at low risk of liver disease
  • Lab Reports
  • HCV Viral Load Test
  • Liver Biopsy/Noninvasive Tests
    • Is there still a role for liver biopsy in managing hepatitis C virus infections?
    • Overview of Liver Biopsy Procedure
    • Three Algorithms of Non-invasive Markers of Fibrosis in Chronic Hepatitis C
    • FibroScan comparison to liver fibrosis biomarkers
  • Chronic HCV Symptoms
    • Fatigue and HCV
    • Sleep Disturbance in Chronic HCV
    • Skin Rash/Hepatitis C
    • Liver Disease: Bone Loss "It Ain't Like Menopause!"
  • HCV Neuropsychiatric symptoms-“brain fog”
    • HCV-Related Nervous System Disorders
    • Hepatitis C Virus and the Brain
    • Liver-induced inflammation hurts the brain
    • The Brain on Fire: Inflammation and Depression
  • Conditions Outside The Liver
    • Prevalence of fibromyalgia among patients with chronic hepatitis C
    • Lichen Planus and The Hepatitis C Virus
    • Dermatologic Disorders and Liver Disease
  • Chronic hepatitis C: Treat or wait?
    • Preparing For Treatment>
      • Starting Hepatitis C Treatment: Tips and Information 2011
      • Adherence To HCV Treatment-Review
      • Treating Hepatitis C; What can you do to increase your chance for SVR?
  • Hepatitis C advanced fibrosis: Treat or Wait
  • Approved Treatments for Hepatitis C
    • Adults:Treating Hepatitis C
    • Interferons and hepatitis C virus
  • HCV Treatment Failure Can Still Mean Less Liver Inflammation
  • Protease inhibitors geno-1:New standard of care
    • Treating HCV Genotype 1 In The Real World
    • 2012 - Direct acting antivirals for the treatment of chronic hepatitis C
    • HCV:End of the Beginning-Possibly-Beginning of the End
    • Patients’ Expectations About New HCV Direct-Acting Antivirals Often Unrealistic
    • What Are NS5A inhibitors ?
    • Hepatitis C Treatment Nonresponders
    • New 2011 AASLD guidelines for treating HCV
    • Treating New and Old Therapies>
      • High-grade liver inflammation may predict treatment response
  • HCV Resistance To New And Experimental Drugs
    • Understanding Resistance in Chronic HCV Infection
  • 2012 Future Prospects-Treatment of HCV
    • Advances in the treatment of hepatitis C virus infection.
  • Boceprevir & Telaprevir
    • FDA Telaprevir/Boceprevir Transcript
    • Pocket Guide Telaprevir/Boceprevir
    • Quick Facts- Direct-acting antivirals Telaprevir/Boceprevir
    • Telaprevir Or Boceprevir: What Is My Chance For A Cure?
  • 2013 News/Incivek (Telaprevir)
    • News/Telaprevir>
      • Telaprevir-IFN/ribavirin Hints at Response
      • Telaprevir FDA Approval>
        • Help-How Do I Take Incivek-telaprevir ?
        • Quick Study Of Telaprevir
        • Cost Of Treating With Telaprevir
  • 2013 News/Victrelis (Boceprevir)
    • News/ Boceprevir>
      • VICTRELIS-Boceprevir: Prescribing-Medication Guide
      • 2011;Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
      • 2011-Boceprevir for Untreated Chronic HCV Genotype 1 Infection
  • Side Effects-Interferon Free Therapies
  • Drug-Drug Interactions In Triple-Therapy
  • 2013/HCV Triple-therapy Side Effects
    • Boceprevir,Telaprevir Less Side Effects?>
      • 2013-HCV therapy geno 1: management of side-effects
      • Dry Mouth and Treatment >
        • Dry Mouth (Xerostomia)
      • Important updates to PegIntron labeling
      • Peginterferon alfa-2a Drug Interactions
      • HCV Treatment: Peginterferon and Ribavirin Side Effects
  • Genotypes/Treatment
    • Treatment Duration in Hepatitis C Virus Genotype 2/3-infected Patients
    • Impact of IL28B on Liver Histopathology in HCV Genotype 2/3
    • Genotype 3/HCV Treatment
    • HCV-Genotype 5 or 6
    • Hepatitis C-Genotype 4>
      • How to optimize HCV therapy in genotype 4 patients
      • Geno 4-Pioglitazone Decreases HCV Viral Load
    • Telaprevir/Boceprevir *genotype 1,2,3
    • (HCV) genotypes in the severity of liver disease
  • What Is The IL28B gene ?
    • Hepatitis C Test:Likelihood of achieving SVR>
      • IL28B and HCV immune responses
  • Index-Current Hepatitis C Drugs In Development
  • 2013-Interferon Free Combinations
    • Interferon-free combinations
    • 2013-Interferon free therapy w-direct acting antivirals for HCV
  • 2013 Sofosbuvir (GS-7977)
    • GS-7977-Formally PSI-7977 >
      • PSI-7977 peg/riba Geno 2/3 PROTON Trial
  • Sofosbuvir(GS7977)/Simeprevir(TMC435)
    • Interferon-Free Combo PSI-7977-TMC435
  • Sofosbuvir (GS-7977)/Ledipasvir (GS-5885)
  • GS-5885, an NS5A Inhibitor
  • ABT-450/r, ABT-267, ABT-333
  • Faldaprevir (BI 201335) and BI 207127 Interferon-Free
    • NS3/4A protease inhibitor BI201335
  • Miravirsen First MicroRNA-Targeted Drug
  • BMS-790052 (Daclatasvir)
  • Daclatasvir/VX135
  • ALS-2200 (VX-135)
  • BMS-790052/BMS-650032 Interferon-sparing
  • (TMC435) Simeprevir
  • TMC435 monotherapy in HCV genotypes 2-6
  • Simeprevir (TMC435) and TMC647055
  • Simeprevir,TMC647055 and IDX719
  • TMC435-daclatasvir-BMS-790052
  • Danoprevir-RG7227 direct-acting antiviral
  • Mericitabine- Polymerase Nuc
  • Sovaprevir (Formerly ACH-1625)
  • ACH-3102 NS5A inhibitor
  • INCIVEK, VX-222/Ribavirin
  • MK-5172 protease inhibitor
  • HCV/New Drug Pipeline
  • 2013/Hepatitis C Clinical Trials
    • Clinical Trials>
      • Learning About Clinical Trials
      • Boceprevir and Telaprevir Trials>
        • Telaprevir REALIZE STUDY
  • HCV Trials/Discontinued Or On Hold
    • Idenix IDX184-Hepatitis C drug
    • TMC435-BMS-986094-formerly INX-189
  • Women's Health; Treating Hepatitis C
    • Early Menopause and Response to HCV Treatment
  • Hepatitis C in Pregnancy
  • Treating Hepatitis C In Children
    • 2012 Hepatitis C infection in children
    • Autoimmunity/Extrahepatic Manifestations in HCV Treatment-Naïve Children
    • Study-long-term safety/durability of virologic response in paediatric patients who were previously treated w-interferon alfa-2b plus ribavirin for 48 weeks
  • Liver Disease in Elderly Patients
  • Dental considerations in patients with liver disease
    • HCV: Dental management-Diagnosis of extrahepatic manifestations>
      • Dental problems delaying the initiation of interferon
  • Fibrosis
    • Is there a natural way to improve liver fibrosis ?
  • 2013 News/Fibrosis
    • News: Fibrosis
  • Cirrhosis
    • What Is Cirrhosis ?
    • Advanced Liver Disease: What Every HCV Treater Should Know
    • The Patient With Cirrhosis: Don't Miss This
    • Hey, I have a question about cirrhosis
    • Physical Findings Suggestive Of Cirrhosis/Photos
    • Staging Cirrhosis>
      • When the Spleen Gets Tough, the Varices Get Going
    • Management Cirrhosis: How Are We Doing?
    • Cirrhosis Regression
    • Cirrhosis ; Surgery in the Patient with Liver Disease
    • Hepatic Encephalopathy>
      • Varices
      • Ascites
      • Management of ascites
  • 2013 News/Cirrhosis
    • News: Cirrhosis>
      • GI Bleeds: Withholding Transfusions Boosts Survival
  • Liver Transplant
    • New HCV Drugs:Expected Risks-Challenges in Liver Transplant
    • Prevention of hepatitis C recurrence after liver transplantation>
      • Effects of Telaprevir on Cyclosporine and Tacrolimus Pharmacokinetics Make Utility in Post-OLT Setting Uncertain
      • HCV Treatment After Liver Transplant
      • Antivirals Ineffective Against HCV After LT
  • 2013 News/Transplant
    • Liver Transplant News
  • Hepatocellular Carcinoma
    • Audio:Liver Cancer
    • Radioembolisation (RE),Selective Internal Radiation Therapy (SIRT)
    • Diagnosis (markers) of early hepatocellular carcinoma
    • Intrahepatic cholangiocarcinoma
    • Treatment TheraSphere/HCC/primary liver cancer
    • Liver Cancer : Microwave Ablation (MWA)
    • Pain May Predict Liver Cancer Prognosis
    • What Is the Indication for Sorafenib in Hepatocellular Carcinoma?
    • Liver Cysts and Tumors"Two Totally Different Concepts"
    • Interactive map of cancer mortality risk worldwide
  • 2013 News/Liver Cancer
    • Liver Cancer News and Updates
    • Vitamin E may lower liver cancer risk
  • Guidelines Nonalcoholic Fatty Liver Disease (NAFLD)
    • Fatty Liver And HCV>
      • Touching some firm ground in the epidemiology of NASH
      • Ultrasound/Liver Biopsy
      • Fatty Liver and Treatment
      • Liver fibrosis/Fatty Liver
  • 2013-Coffee and Liver Disease
  • Liver Regeneration
  • Liver Health
    • Choline: Great for the Liver
    • Medications for sleep in liver disease
    • The odds of gallbladder disease in Hepatitis C Patients
    • HCV & Gallbladder Disease:
    • Enlarged Spleen
    • HCV And Cardiovascular Risk
  • Nutrition-Herbs-Vitamins
    • Vitamin D and Treatment
    • Liver Disease - The Mediterranean Diet
    • Diet: Cirrhosis>
      • Low-Salt Diet-A Must in Cirrhosis
      • Diet for Liver Disease Low Sodium and More
      • Vitamin B12 supplements may help treat hepatitis
      • Nutrition in end-stage liver disease
      • Cirrhosis; Vitamin K Deficiencies
      • Vitamin D Levels In Cirrhosis
      • Vitamin D could de-stress Liver Disease Treatments
      • Drugs And Cirrhosis
      • Cancer and Berries
  • 2013-Silymarin for HCV infection
  • Milk Thistle
    • 2012-Milk Thistle No Help in Tough Hepatitis C Cases
    • Silymarin-Milk Thistle for NAFLD
    • Milk thistle"- Silibinin in hepatitis C related liver transplantation
    • Milk Thistle is coming to America
    • Caution! Herbs and Nutritional Supplements
  • HCV Drugs: Financial Support
  • HCV Filing For Social Security
  • Hepatitis C: A Rational Call To Arms
    • Hepatitis C; A Forced Legacy
    • Outsourcing:Globalization of the pharmaceutical industry>
      • Inspirational
  • Hepatitis C Links / Best On The Web
    • Chat and Message Boards
  • Whose Website Is This ?
  • Feedback/Contact Us

Hey, I have a question about this IL28B gene and hepatitis c treatment.........

Picture
2013 - Feb
IL28B genotype had limited effect on telaprevir response in HCV patients

2013 - Jan
Targeting hepatitis C treatment: The importance of interleukin (IL)-28


View All News And Research Here


Quest Diagnostics Launches Hepatitis C Virus Therapy Test Based on IL28B Gene Variants




What is a gene?
A gene is the basic physical and functional unit of heredity. Genes, which are made up of DNA, act as instructions to make molecules called proteins. In humans, genes vary in size from a few hundred DNA bases to more than 2 million bases. The Human Genome Project has estimated that humans have between 20,000 and 25,000 genes.
. . .
Every person has two copies of each gene, one inherited from each parent. ..

Most genes are the same in all people, but a small number of genes (less than 1 percent of the total) are slightly different between people. .
Alleles are forms of the same gene with small differences in their sequence of DNA bases. These small differences contribute to each person’s unique physical features.

Picture
Genes are made up of DNA. Each chromosome contains many genes.
Source

How is the IL28B gene related to Hepatitis C ?
Variations in the IL28B gene have recently been linked to better treatment response among people with chronic hepatitis C virus

What is the official name of the IL28B gene?
The official name of this gene is “interleukin 28B (interferon, lambda 3).”

What The Heck Does That Mean ?
Background From Liz Highleyman ,

As background, the relevant variations—known as single nucleotide polymorphisms (SNPs), or substitution of a single building block at a specific position in the DNA chain—are located on chromosome 19 near the IL28B gene. The IL28B gene encodes instructions for making interferon lambda (a.k.a. interleukin 28). Interferons produced by the body are key to the immune system's response against hepatitis C and B; interferon therapy strengthens this natural response. ,

Will Someone Tell Me What a single nucleotide polymorphisms (SNPs) Is ?
Single nucleotide polymorphisms, frequently called SNPs (pronounced “snips”), are the most common type of genetic variation among people. Each SNP represents a difference in a single DNA building block, called a nucleotide. For example, a SNP may replace the nucleotide cytosine (C) with the nucleotide thymine (T) in a certain stretch of DNA.
.. .
SNPs occur normally throughout a person’s DNA. They occur once in every 300 nucleotides on average, which means there are roughly 10 million SNPs in the human genome. Most commonly, these variations are found in the DNA between genes. They can act as biological markers, helping scientists locate genes that are associated with disease. When SNPs occur within a gene or in a regulatory region near a gene, they may play a more direct role in disease by affecting the gene’s function. .

Most SNPs have no effect on health or development. Some of these genetic differences, however, have proven to be very important in the study of human health. Researchers have found SNPs that may help predict an individual’s response to certain drugs, susceptibility to environmental factors such as toxins, and risk of developing particular diseases. SNPs can also be used to track the inheritance of disease genes within families. Future studies will work to identify SNPs associated with complex diseases such as heart disease, diabetes, and cancer.
 Source

What Are Alleles?
Alleles are corresponding pairs of genes located at specific positions in the chromosomes. Together, alleles determine the genotype of their host organism. .
For example, the alleles for eye color are found on chromosomes 15 and 19, and depending on which alleles someone has, he or she may have blue, brown, green, gray, or hazel eyes, and sometimes a mixture of these traits is present. Source

  What Are "C" and "T" Alleles ?
As mentioned above a person inherits two copies of each gene; one from each parent to make up each allele. The IL28B rs12979860 SNP has two alleles or variations which are regonized as "C" and "T". .

Then What Is C/C or "CC" ?

In Hepatitis C patients who have the C/C pattern simply means that they have two copies of the "C" allele.

Then What Is T/T or "TT" ?
The same is true in Hepatitis C Patients who have the T/T pattern or two "T" alleles .

What Does This Mean To The Heptitis C Patient?
Hepatitis C Patients With The C/C pattern or two "C" alleles have the best response to HCV therapy..
As for the T/T pattern or two "T" alleles they have the least response to therapy. .

What If A Person Has The C/T pattern?
The C/T pattern would mean the person has one copy of each allele. These people would fall somewhere in between. 

Source For The Explanation Of "C" and "T" alleles collected from HCV Advocates Article "IL28B Gene Highlighted at AASLD—Liz Highleyman"

Summarize All Of This Please
TT - Poorest response to Hepatitis C treatment.
CC - Best response to Hepatitis C treatment.
CT - Somewhere in between TT and CC alleles.

Non-genetic and genetic factors play a part in determining whether PEG-IFNalpha/RBV therapy will work. Recent research has identified several inherited variations near the interleukin 28B (IL28B) gene that could eventually help doctors identify those people with hepatitis C for whom the standard treatment is doomed to fail.
See: Response to Hepatitis C Treatment

** Note: It has been proven that people of European descent more commonly have the C/C pattern this may explain why white patients infected with HCV respond better then black patients.

Is There A Test For The IL28B Gene?
LabCorp Launches Interleukin 28B Polymorphism (IL28B) Genotype Test to Support Individualized Treatment Decisions for Patients with Hepatitis C Viral Infection.
Service Announcement >> .

From HCV Advocate Note: The term CC genotype used to describe the variation of IL28B is not same as the term used for different strains of HCV (called genotypes)–numbered 1 through 6. ..


Excerpt From HCV Advocates Newsletter

The Gene that Predicts--
Alan Franciscus, Editor-in-Chief.

At this point, many people are interested in receiving the IL-28B assay to help determine their chances for successful Hepatitis C treatment. Unfortunately, most insurance companies do not currently cover this pricey test. While several individuals have reported that some Hepatitis C clinical trials may include this test in their screening protocol, the majority of those with this virus may not be able to obtain it yet. The time needed for such a policy change within health insurance companies can be a positive or a negative. .
On the plus side, knowing your IL-28B allele combo can better guide a doctor and patient toward a custom-tailored Hepatitis C treatment regimen..
On the other hand, revelation of a TT allele combo could be cause for an insurance company to deny treatment coverage. Regardless of what tests are currently covered by health insurance companies, there is little doubt that Hepatitis C treatment is becoming increasingly specialized. Besides knowing the Hepatitis C genotype you are infected with, each person will eventually need to know which nucleotides are on the IL-28B segment of his or her genome. Being armed with specific genetic information about the virus and specific genetic information about the infected person will help practitioners construct the best possible Hepatitis C treatment plan for their patients.

Continue reading...........

Links:..,

Nov 2010
IL28B Gene Patterns and Liver Transplant Outcomes in Hepatitis C Patients
SUMMARY: Variations in the IL28B gene, which are associated with spontaneous hepatitis C virus (HCV) clearance and response to interferon, also appear to influence the speed of HCV recurrence, treatment response, and complications after liver transplantation, according to 2 studies presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) in Boston. Transplant outcomes were linked not only to the IL28B pattern of the recipient, but also variations in the new donor liver..
Do IL28B Gene Variations Affect Liver Disease Progression in People with Hepatitis C ? .

June 2010
An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response .
Hepatitis studies: IL28B genetics, HCV survival, FibroScan in acute HCV, MSM reinfection and responses to transplantation.

July 2010
Are We on the Verge of Gene-Based Personalized Treatment for Hepatitis C Virus Infection?

From Medscape Gastroenterology William F. Balistreri, MD
Data presented at Digestive Disease Week 2010 further indicated that we can predict sustained virologic response on the basis of emerging validation of the genetic variation in regulation of the immune response to HCV.[13] The specific IL28B polymorphism (C/C, which occurs in up to 33% of patients) is strongly associated with reduced expression of intrahepatic ISGs and the response rate to PegIFN and ribavirin. Genetic variation in IL28B regulates the innate immune response to HCV in the liver, priming patients for a stronger response to exogenous IFN alpha therapy.[13]
Thus, at least 5 independent studies provide overwhelming genetic evidence for the role of IL-28B in the pathogenesis of HCV infection and in spontaneous and treatment-related recovery from HCV infection. Future studies will link these findings to improved, and perhaps personalized, HCV treatment and prevention worldwide.

May 2010
Reaping the Early Harvest of the Genomics Revolution - IL28B gene predicts response to Peg/Rbv SVR in Caucasians & African-Americans- Editorial
Gastroenterology May 2010 Raymond T. Chung (Associate Editor) Much fanfare heralded the successful sequencing of the human genome in 2003. Newly armed with a comprehensive understanding of the human genetic map, investigators proclaimed that personalization of medicine was imminent. Now, 7 years after this signal discovery, where do we stand in the delivery on this promise to clinical care?

Jan 2010
IL28B gene variation predicts response to hepatitis C treatment: will it change treatment of co-infection?
Variations in the IL28B gene that have recently been linked to better treatment response among people with chronic hepatitis C virus infection may also predict recovery in HIV/HCV-coinfected people..


Abstracts


HCV Advocate
IL28B Gene Highlighted at AASLD
Liz Highleyman

The Gene that Predicts
Alan Franciscus, Editor-in-Chief

Also See ; Hepatitis C Test: Likeihood Of Achieving SVR


VIDEO March 2010

Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure...

AmerGastroAssn
March 23, 2010
Dr. Andri Rauch discusses his manuscript "Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study."
To view the print version of this abstract go to: http://tiny.cc/kdnlw
 
Copyright 2010-2013 Hepatitis C New Drug Research And Liver Health